ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $133,137 | -44.8% | 25,073 | -1.0% | 0.00% | – |
Q2 2023 | $241,290 | -8.7% | 25,319 | +5.4% | 0.00% | – |
Q1 2023 | $264,330 | +6.1% | 24,030 | +42.7% | 0.00% | – |
Q4 2022 | $249,158 | -30.0% | 16,835 | -9.6% | 0.00% | – |
Q3 2022 | $356,000 | -92.0% | 18,621 | -91.1% | 0.00% | -100.0% |
Q2 2022 | $4,458,000 | +1954.4% | 209,175 | +1757.8% | 0.00% | – |
Q1 2022 | $217,000 | -5.2% | 11,259 | +1.8% | 0.00% | – |
Q4 2021 | $229,000 | -27.1% | 11,060 | -15.7% | 0.00% | – |
Q3 2021 | $314,000 | -5.1% | 13,114 | +8.5% | 0.00% | – |
Q2 2021 | $331,000 | – | 12,085 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |